StockDuty ← Dashboard Oct 29, 2026 08:34 PM ET
SignalEarnings

Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark

Q3 earnings beat estimates while revenues missed, signaling mixed financial performance.

What happened: Amarin reported Q3 2026 adjusted earnings of eight cents per ADS, beating the Zacks Consensus Estimate of a 15 cent loss, while total revenues of $39.6 million missed the $45 million estimate. Key numbers: Adjusted EPS 8 cents, down 57.9% YoY. Revenue $39.6 million, down 20.4% YoY. Why it matters: Revenue weakness stemmed from lower U.S. product sales amid generic competition and pricing pressure, though global in-market demand for Vascepa/Vazkepa rose an estimated 55% YoY. Management expects U.S. volumes to remain broadly stable and sustained positive cash flow in 2026. Market: +1.0% today ($21.35), +68.6% YTD, 1.4x vol — as of 20:17 UTC Coverage: 8 outlets in 24h
Amarin reported Q3 2026 adjusted earnings of eight cents per ADS, beating the Zacks Consensus Estimate of a 15 cent loss, while total revenues of $39.6 million missed the $45 million estimate.
Revenue weakness stemmed from lower U.S. product sales amid generic competition and pricing pressure, though global in-market demand for Vascepa/Vazkepa rose an estimated 55% YoY. Management expects U.S. volumes to remain broadly stable and sustained positive cash flow in 2026. Market: +1.0% today ($21.35), +68.6% YTD, 1.4x vol — as of 20:17 UTC
Sources